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Antibody Mediated Rejection of Human Liver Allografts: 
Transplantation Across ABO Blood Group Barriers 
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L IVER ALLOGRAfTS are resistant to hyperacute or 
antibody mediated rejection from preformed antibod-
ies. No consistent syndrome develops following transplanta-
tion when a recipient harbors preformed Iymphocytotoxic 
antibodies.1.2 The only apparent deleterious effect of pre-
formed Iymphocytotoxic antibodies is a higher incidence of 
the "vanishing hile duct syndrome.") Despite these clinical 
observations. a phenomenon akin to "hyperacute" rejection 
can be seen following liver transplantation in experimental 
animals who were previously sensitized to donor antigens.·" 
Additionally, isolated case reports thought to represent 
hyperacute rejection of the liver in humans, have appeared 
over the years.6•1 However. no pathophysiologic mechanisms 
or means of predicting its occurrence in humans have been 
proposed. The following study was designed to address this 
problem. 
The syndrome of hyperacute rejection was first recognized 
in renal transplantation when crossing ABO blood group 
barriers.' A similar process developed when a recipient 
harbored preformed Iymphocytotoxic antiOOdies.9 We there-
fore took advantage of this historical perspective and 
embarked on a detailed study of liver allografts across ABO 
blood group barriers. 
Analysis of the patient's course and pathology specimens 
revealed a significantly (p < 0.05) higher rate of early graft 
failure (d weeks) in ABO incompatible (ABO-I) grafts 
when compared to ABO compatible (ABO-C), age. sex and 
priority matched controls. Study of these cases allowed for 
the recognition of antibody mediated rejection of human 
liver allografts and for the development of criteria for 
esta blishing the diagnosis. 
MATERIALS AND METHODS 
Case Selection 
All adult and pediatric patients who received a primary ABO 
incompatible liver graft (non 0 ~ O. AB ~ non AB. B -. A, or 
A - B) at the L'niversity of Pittsburgh between 1981 and 1987 were 
studied. The age. se~ and priorit), status of each of the A BO·' cases 
was recorded. Priorit) status refers to the condition of the patient 
prior to transplantation. Priority 1 patients are the least sick and 
those with a priority of 6. are in the intensive care unit on ventilatory 
support. These primary ABO· I cases were then compared to two 
groups of control patients. 
All patients at the Cniversity of Pittsburgh received a sequential 
OL T number to designate their position in the series and the time of 
their initial transplant operation. The first group of controls was 
selected on the basis of the time of initial liver transplantation by the 
OL T number. These are referred to subsequently as "clinical" 
controls. For example, if a patient receiving an ABO-) liver graft was 
given OL T 1003. the immediately prior and consecutive age 
matched. ABO-C patient was selected as a control. Therefore. each 
ABO-) patient had two controls. However. in some cases the ABO-) 
cases were close or consecutive in OL T number. When this occurred. 
a single case was used as a control for two different ABO-' cases. 
The age, se~ and priority status of each of these controls were 
recorded. The results of the T·warm Iymphocytotoxic crossmatch in 
this group were not considered. The numerical method of selecting 
control cases was chosen to compensate for the variable handling of 
patients over the years. 
Initial analysis of the data from the two groups revealed a much 
higher incidence of early graft failure because of hemorrhagic 
necrosis in the ABO-) compared to the ABO-C clinical control 
group. Therefore. we chose a second control group, referred to as 
"pathologic" controls. This group consisted of 10 ABO-C, cross-
match negative patients. transplanted over the same period of time, 
who also lost their grafts within the first several weeks. These cases 
were chosen as histo- and immunopathologic controls since we 
hypothesized that all early graft failures may have a similar appear-
ance, unrelated to prior sensitization. However, we did exclude 
patients with a positive T·warm Iymphocytotoxic crossmatch from 
this group since it was possible. but unlikely, that the sensitization 
led to early graft failure. 
Patient Demographic Data 
There were 24 patients (5 adults. 19 children) who received primary 
ABO· I hepatic grafts. The clinical control group contained 38 
patients (10 adults. 28 children). These two groups were compared 
for graft survival. and will be referred to as the "study group." The 
study group was primarily pediatric; a'erage for pediatric patients 
was 5.8 years and for adults 45.3 years. with 48 (77%) under the age 
of 18 at the time of transplantation . Among the ABO·I patients. 83% 
.... ere under the age of 18 compared with 74'7c in the control group 
(p > 0.05). The overall distribution of the priorit) scores did not 
differ significantl) betlloeen these two groups (p > 005). 
Pathologic Studies 
All pathologic specimens from the three groups were reviewed. 
Particular attention was given to histopat hologic findings of platelet· 
fibrin thrombi, vasculitis, congestion, hemorrhage. neutrophilic exu· 
dation and ischemic necrosis. Evidence for the deposition of IgM, 
IgG. IgA. C lq, C3. C4. and fibrinogen was sought for in the ABO·I 
cases and pathologic controls using a direct immunofluorescent and 
an indirect immunoperoxidase technique. 
Elution studies were performed as follows. Frozen graft tissue (2-5 
grams) were minced with the use of a tissue homogenizer. The tissue 
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was washed (4x) in 6% bovine albumin in the 4°C. A heat elution 
was performed at 56°( for fifteen minutes into 2·) ml of albumin. 
then the ti:;sue was centrifuged at 4.500 xG for five minutes. The 
supernatant was tested by hemaglutination against A" B and a red 
cetls with readings at immediate spin. 30 minutes and 37°C in 
polyspecific antiglobulin. The immunoglobulin class of eluted anti-
bodies was determined by a) the use or anti-lgG anti-globulin 
re-agent and treatment with dithiothreitol to ina.:tivate IgM. The 
last wash solution was tested negative for ABO antibody served as 
control. Testing was performed without knowledge of the donor 
and/or recipient ABO types. 
RESULTS 
Graft Survival Analysis 
All patients in the study group were followed for a minimum 
of 30 days (up to 2,141 days). The results are shown 
graphically in Fig I. Among the clinical controls 4 (II %) of 
grafts failed within 30 days, compared to II (46%) of the 
primary ABO-I cases (p < 0.05). A ratio of graft failure 
within 30 days of transplantation defined by each of the 
independent variables (gender, age group and priority sta-
tus) at the time of transplant was calculated. A statistically 
significant (p < 0.05) odds ratio greater than I, implying a 
greater risk of early graft failure among those receiving 
incompatible grafts than among those receiving compatible 
grafts, was found for females, pediatric patients and for 
patients in the hospital (not in the leU) at the time of 
transplantation. A multi-variant model (logistic regression) 
was used to determine whether there was an effect of ABO 
compatibility on graft survival, simultaneously adjusting for 
the effect of gender. age and priority status. When the full 
model was fit, a statistically significant effect (p < 0.05) was 
found for ABO compatibility but not for anv of the other 
independent varia bles. The adjusted odds rati~ was 11.8 with 
a 95'iC confidence interval of (2,5. 56.6). This implies that 
adjusting for age. gender and priority status. the odds of a 
recipient suffering graft failure within the first 30 days of 
liver transplantation is about 12 times greater among those 
receiving incompatible than among those receiving compati-
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Fig 1. Comparison of graft survival in first 30 days post· 
transplantation of ABO-I and ABC>-C liver allografts_ 
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ble grafts, ~one of the other independent variables (age, sex, 
or priority status) examined were found to be statistically 
significant (p > 0,05). adjusting for a case or control status. 
Individual Case Analysis 
A detailed review of each patient's clinical course and 
subsequent classification was performed and reported else-
where. 'o In summary, among the ABO-' patients 10 (42%) 
still have functional grafts. Fourteen of these patients (58%) 
have experienced graft failure and were retransplanted or 
expired. Four of these graft failures were directly attribut-
able to humoral rejection due to preformed isoagglutinins. In 
eight others, humoral rejection was thought to playa signifi-
cant, if not the primary role in graft failure. Recurrent 
hepatitis B was responsible for graft failure in one case. In 
the remaining patient. there was evidence of antibody 
mediated graft damage. but graft failure was temporally too 
remote (147 days) from the operation to implicate antibodies 
as the primary reason for graft failure. The average graft 
survival for failed graft was 32 days. However, most of the 
grafts that failed, did so within the first 2·3 weeks. The few 
late graft failures skewed the mean. 
In the clinical control group, 24 (63%) of the grafts are 
still functioning, However, the ca uses of gra ft failure differed 
significantly from that seen in the primary ABO-I group. 
Additionally, the average graft survival for failed grafts in 
this group was 197 days; significantly (p < 0.05) longer than 
the failed primary ABO-I grafts. 
Among the pathology controls, all experienced graft fail-
ure within the first two weeks, Eight grafts failed from 
hepatic arter) or iliac graft thrombosis and/or arterial mural 
dissection. which according to the operating surgeon, was 
explainable on technical grounds, One patient had no portal 
vein for anastomosis requiring an alternative, but unsuccess-
ful. venous anastomosis, The cause of graft failure in the 
remaining patient was determined to be the result of preser-
vation injury. 
Pathologic Findings 
A majority of the pathologic samples were taken as a result 
of the onset of early graft dysfunction. However. protocol 
pre- and post-implantation biopsies were available in five 
patients. The following description is a summary of the 
pathologic findings from several ABO-I cases, 
Pre-implantation biopsies generally contained minimal to 
no pathologic alterations. Samples taken 2-6 hours after 
implantation showed a rather impressive clustering of neu-
trophils. fibrin deposition and red blood cell sludging in the 
sinusoids, This was seen in association with focal hemorrhage 
in the space of Disse. focal hepatocellular aggregation or 
single cell acidophilic necrosis. Biopsies one to two days later 
continued to show the above changes but in addition, small 
clusters of hepatocytes demonstrating coagulative necrosis 
were seen. Small portal arteries mayor may not show 
fibrinoid degeneration or inflammation at this time. A mild 
neutrophilic portal exudate may begin to appear with focal 
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duct proliferation as a sign of regeneration. At this stage. the 
histologic changes can be quite difficult if not impossible to 
separate from those of prolonged preservation injury. There-
after. a progressive patchy geographic hemorrhagic infarc-
tion of the organ ensues. The early progression of the changes 
mayor may not be detecta ble in biopsies because of the 
patchy nature of the process and subsequent sampling prob-
lems. Once the process is widespread. coagulopathy. submas-
sive or massive necrosis and hepatic failure become evident 
necessitating retransplantation. 
Gross examination of failed ABO-I grafts revealed 
enlarged, hemorrhagic organs mottled with random areas of 
necrosis with or without large vessel thrombosis. The capsule 
had actually ruptured in one liver. 
Microscopically. focal fibrinoid necrosis or inflammatory 
vasculitis of small or medium size arteries was detectable in 
only four cases. More prevalant findings included arterial 
and venous endothelial cell reactivity. with mild lumenal 
platelet and neutrophil sludging. The most evident finding 
was the presence of focal fibrin masses attached to a partially 
disrupted vascular wall. extending in a flame-like fashion 
into the vessel lumen. These were particularly common in 
venous channels. However, similar arterial deposits could 
also be seen. Throughout the hepatic parenchyma most all 
A BO-I cases showed severe and widespread geographic Jreas 
of hemorrhagic necrosis. The necrotic tissue was intermixed 
with neutrophils and there was often no particular zonal 
distribu tion. 
Clinical and Pathologic Control Cases 
Pathologic specimens from the clinical control group showed 
little resemblance to the findings described in the ABO-I 
cases. The exception to this statement is that biopsies 
obtained in the first several days post·transplant from con-
trols often contained focal sinusoidal neutrophil clusters. 
congestion and mild acidophilic necrosis of hepatocytes 
similar to that described in the early course of the ABO-I 
patients. However. the magnitude of these changes in the 
control groups was less than those seen in the ABO-I group. 
Failed grafts from the pathologic control group with 
arterial thrombosis and hilar abscesses. demonstrated areas 
of necrosis which appeared reminiscent of necrosis seen in 
the ABO-I livers. However. necrotizing and/or inflamma-
tory vasculitis was not found. 
Immunofluorescent Studies 
All cases categorized as primary antibody mediated rejection 
demonstrated the presence of focal but intense deposition of 
IgM and C I q. with lesser amounts of C3. usually in the 
arterial walls. Focal IgG deposits were found in only one 
graft. Patchy sinusoidal and venous staining could also be 
seen but was much less impressive than deposits in the 
arteries. In general. the arterial deposits were not uniformly 
distributed throughout the liver. In fact some subcapsular 
sections were negative while those taken closer to the hilum 
demonstrated impressive arterial deposition. Sequential 
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staining of biopsy specimens from several ABO-I cases 
revealed intense IgM. IgG and C3 in the sinusoidal, arterial 
and venous systems. prior to graft failure. However, exami-
nation of the immunofluorescent staining days or weeks later 
contained only focal IgM and C I q in the arteries. 
In the pathology controls. focal deposition of IgM and IgG 
was seen in only one liver. from a patient who had a weakly 
positive crossmatch. All other cases were negative. Sinusoi-
dal staining for Clq and fibrinogen was frequently positive in 
both the ABO-I and the ABO-C livers, particularly in and 
around the central vein region. This was considered to be a 
non-specific finding; the result of leakage through a dam-
aged sinusoidal wall or through Kupffer cell phagocytosis. 
Although not included in this study. we have seen several 
examples of non-specific leakage of IgM into the wall of 
medium-sized arteries of grafts with arterial thrombosis at 
the anastomosis. In general, these deposits were less intense 
and accompanied by the leakage of other serum components 
such as fibrinogen and albumin. 
Elution Studies 
Tissue eluates from failed primary ABO-! allografts, which 
were thought to demonstrate primary antibody mediated 
rejection all showed reactivity against the donor ABO anti-
gens (N = 4). Analysis of the reactivity using dithiothreitol 
and anti-lgG antiglobulin reagent gave results characteristic 
of the IgM antibody class, identical to that found within the 
tissues. Eluates of tissues from three of the liver pathology 
controls were negative for isoagglutinin activity. 
Clinical Observations 
A clinical diagnosis of hyperacute rejection. that is a graft 
after initial adequate reperfusion .... hich becomes cyanotic. 
mOllled. flaccid and fails to produce bile was not made in this 
group of patients. However. retrospectively several surgeons 
recall a swelling and "hardening" of the ABO-I livers. three 
to fours hours after reperfusion. The only other possible clue 
to future complications in the immediate reperfusion period 
was the detection fibrinolysis and difficulty in achieving 
hemostasis. 
The first several days posl·transplant most patients with 
ABO-I grafts experienced a relentles~ rise in serum transam-
inase values. signaling a catastrophic event. Angiograms and 
percutaneous biopsies were often performed to rule out 
arterial thrombosis or other definable causes of graft mal-
function. Arterial angiography in one case was particularly 
striking (Fig 2); it demonstrate~ a markedly narrowed 
arterial tree. This diffuse narrowing was thought to be the 
result of diffuse arterial spasm. The rise in transaminase 
values was followed by bleeding and hepatic failure. 
The appearance of the organs at re-transplantation was 
similar to kidneys undergoing "hyperacute" rejection. They 
were enlarged, mottled and cyanotic. The gross intraopera-
tive appearance of one graft was particularly impressive. The 
organ was massively enlarged. cyanotic. had a capsular 
rupture and was bleeding from the surface. 
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Fig 2. Severe and diffuse narrowing of the entire allograft 
Intrahepatic arte,lal tree demonstrated on selective aortic 
cOhdult arteriogram two weeks following lI ... er transplanta' 
tion. 
DISCUSSION 
The results of this study demonstrate that liver allografts are 
susceptible to antibody mediated (hyperacute) rejection 
from preformed (i90agglutinins) antibodies. The diagnosis. 
however. should be limited to cases which meet all of the 
following criteria: I) early graft failure with no alternative 
clinical or pathological explanation. 2) consistent light 
immunofluorescent microscopy findings. 3) demonstration of 
a pre· sensitization stated in the recipient and 4) presence of 
donor ,pecific antibodies in a tissue eluate from the failed 
graft. Strict adherence to these criteria will prevent over· 
diagnosis. since a similar clinical course and hemorrhagic 
necrosis of the graft may occur in a variety of settings, 10 
Hyperacute rejection of a human liver allograft has not 
been previously documented It has been convincingly demo 
onstrated that Iymphocytotoxic antibodies have relatively 
little effect on the immediate post·transplant course. I·) How· 
ever, no detailed observat:ons of a series of ABO·' human 
liver grafts has been reported. The indepth study of these 
patients has allowed us to recognize both the clinical and 
pathologic syndrome that develops following transplantation 
in the face of a specific type of preformed antibody. Further-
more. recognition of the syndrome then paved the way for the 
development of the above criteria to substantiate the diag· 
nosis. 
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The pathophysiologic mechanisms underlying the cause of 
graft failure in hyperacute liver allograft rejection are proba· 
bly similar to those in kidney or heart grafts, However. some 
noticeable differences may help us understand the phenome-
non of hyperacute rejection in general. Undoubtedly. endo-
thelial damage from preformed antibodies is the initial event. 
Conventionally. this was thought to be followed by diffuse 
intra-organ coagulation. which was responsible for the 
ischemic necrosis. However, in liver allografts although 
platelet and neutrophil sludging can be identified, more 
common is the finding of venous and arterial fibrin deposi-
tion. Also. the dynamic observations of diffuse arterial spasm 
may be of importance. since it is thought to playa prominent 
role in hyperacute rejection in animal modelsu,ll 
Finally, we have recognized that antibody mediated (hy· 
peracute) rejection of the liver exists. and crudely identified 
its characteristic features. However, much work needs to be 
done in this area. A search must be made for other antibodies 
which may be implicated in early graft failures, Presently, it 
appears that T·warm Iymphocytotoxic antibodies are 
unlikely candidates in most situations. However, as yet 
unidentified antigen·antibody systems may be operative, 
since a significant percentage of early graft failures remains 
unexplained (unpublished observation), 
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